Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366002 · ClinicalTrials.gov registry record · Phase 4
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
NCT00366002 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 500 participants.
The verdict
NCT00366002, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
Study Summary
This study will evaluate safety, efficacy and patient's perception of outcome after treatment with darifenacin (7.5 mg once daily (o.d.) with voluntary increase up to 15 mg o.d.) in patients with OAB who are dissatisfied with prior oxybutynin extended release (ER) or tolterodine extended release (ER) therapy.
Interventions
- DRUG Darifenacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366002
The ClinicalTrials.gov registry entry for NCT00366002 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Darifenacin is the first listed.
NCT00366002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366002 about?
NCT00366002 is a clinical study titled "Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder". This study will evaluate safety, efficacy and patient's perception of outcome after treatment with darifenacin (7.5 mg once daily (o.d.) with voluntary increase up to 15 mg o.d.) in patients with OAB who are dissatisfied with prior oxybutynin extended release (ER) or tolterodine extended release (ER...
What is the current status of trial NCT00366002?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2006-06. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00366002?
The interventions under investigation include: Darifenacin (DRUG).
Who is sponsoring clinical trial NCT00366002?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.